Latest in Cardiology from ACC.org

• ACC Launches New Program to Improve HF Care
  The ACC has launched a new program, Transform HF Care: New Horizons in Treatment, to educate clinicians on the latest advances, medications and interventions emerging in heart failure (HF) management and treatment.
• ACCEL Lite: ODYSSEY-HCM: Mavacamten in nHCM
  In this interview, Matthew Martinez MD, FACC and Milind Y. Desai, MD, MBA, FACC discuss “ODYSSEY-HCM: Mavacamten in nHCM.”
• ACC CardiaCast: Courtside with the Chair: CV Care of the Masters Athletes - Part 2
  This episode is Part 2 of CV Care of the Masters Athlete where Dr. Jonathan Kim continues the discussion with Drs. Eugene H. Chung, Ankit B. Shah, and Jeffrey J. Hsu on the cardiovascular (CV) care of the masters athlete.
• Top Posters at ACC Middle East 2025 Address High Non-HDL-C, RV Impairment, Flurpiridaz F 18 PET MPI
  As the ACC Middle East 2025 Together With 16th Emirates Cardiac Society Conference winds down in Dubai, UAE, the three winners of the conference's abstract competition were announced and invited to present at ACC.26 in New Orleans, LA.
• Dual Antiplatelet Therapy May Reduce Stroke Risk After Valve-in-Valve TAVI
  When compared with single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT) after valve-in-valve TAVI to treat surgical bioprosthesis dysfunction may be associated with a lower one-year stroke incidence, according to a study presented at the 46th National Congress GISE 2025...